journal
MENU ▼
Read by QxMD icon Read
search

Clinical Advances in Hematology & Oncology: H&O

journal
https://www.readbyqxmd.com/read/29851933/the-use-of-chimeric-antigen-receptor-t-cells-in-patients-with-non-hodgkin-lymphoma
#1
Premal D Lulla, LaQuisa C Hill, Carlos A Ramos, Helen E Heslop
Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphoma. A major contributor to the success of immunotherapy has been the advent of genetic engineering technologies that introduce a chimeric antigen receptor (CAR) into T cells to focus their killing activity on tumor cells...
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851932/managing-adverse-effects-of-immunotherapy
#2
James N Gerson, Chethan Ramamurthy, Hossein Borghaei
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy...
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851931/does-adjuvant-therapy-for-high-risk-melanoma-with-either-immunotherapy-or-targeted-therapy-affect-therapeutic-choices-at-relapse
#3
Michael A Postow
No abstract text is available yet for this article.
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851930/how-i-treat-chemorefractory-metastatic-colorectal-cancer
#4
Edward Chu
No abstract text is available yet for this article.
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851929/how-should-braf-v600e-mutated-colorectal-cancer-be-treated
#5
Scott Kopetz
No abstract text is available yet for this article.
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851928/the-evolution-of-poly-adp-ribose-polymerase-inhibitors-in-the-treatment-of-breast-cancer
#6
Susan M Domchek
No abstract text is available yet for this article.
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851927/enasidenib-for-relapsed-refractory-acute-myeloid-leukemia-with-idh2-mutations-optimizing-the-patient-experience
#7
Gail J Roboz
No abstract text is available yet for this article.
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851939/highlights-in-cytomegalovirus-from-the-2018-bmt-tandem-meetings-commentary
#8
Sanjeet Singh Dadwal
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851938/highlights-in-cytomegalovirus-from-the-2018-bmt-tandem-meetings
#9
(no author information available yet)
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851937/management-of-relapsed-refractory-follicular-lymphoma
#10
Peter Martin
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742084/first-line-use-of-novel-hormonal-agents-in-prostate-cancer-a-critical-appraisal
#11
Derek Raghavan
Castration has been the hallmark of the treatment of advanced prostate cancer for nearly a century. Conventional surgical or medical castration for the management of metastatic prostate cancer has been associated with an initial response rate greater than 60% to 70%, depending on the criteria employed. The median duration of the initial response is usually less than 3 to 5 years, however, depending on the extent of disease. The failure of disease to respond to castration has been associated with an increase in the production of adrenal androgens and/or the evolution of upregulated or mutated androgen receptors...
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742083/update-on-signal-inhibitors-in-chronic-lymphocytic-leukemia
#12
Prajwal Boddu, Nitin Jain
The last decade has seen major progress in our understanding of the pathobiology of chronic lymphocytic leukemia (CLL) and the identification of potential new therapeutic targets. As a result, researchers have developed novel targeted therapies, several of which are already approved and many of which are in advanced stages of clinical development. These new agents are much less toxic than chemoimmunotherapy and may be preferred for their superior efficacy in patients with certain high-risk features, such as del(17p)...
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742081/looking-ahead-to-new-therapies-in-small-cell-lung-cancer
#13
Charles M Rudin
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742080/bayesian-approaches-to-evaluating-doses-of-drugs
#14
Gary L Rosner
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742079/current-approaches-to-pregnancy-and-childbirth-in-women-with-von-willebrand-disease
#15
Jill M Johnsen
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742078/enasidenib-for-patients-with-relapsed-acute-myeloid-leukemia-and-the-idh2-mutation
#16
Courtney DiNardo
No abstract text is available yet for this article.
April 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851936/highlights-in-acute-myeloid-leukemia-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition-commentary
#17
Courtney DiNardo
No abstract text is available yet for this article.
March 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29851935/highlights-in-acute-myeloid-leukemia-from-the-2017-american-society-of-hematology-annual-meeting-and-exposition
#18
(no author information available yet)
No abstract text is available yet for this article.
March 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742088/highlights-in-metastatic-colorectal-cancer-from-the-2018-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium-commentary
#19
Axel Grothey
No abstract text is available yet for this article.
March 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29742087/highlights-in-metastatic-colorectal-cancer-from-the-2018-american-society-of-clinical-oncology-gastrointestinal-cancers-symposium
#20
(no author information available yet)
No abstract text is available yet for this article.
March 2018: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"